drugset / Trial / NCT04476407

Pharmacokinetics of Benapenem in Subjects With Renal Impairment

NCT04476407

Phase 1 Completed 18 enrolled Sihuan Pharmaceutical Holdings Group Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multiple center, parallel-group Study to compare the pharmacokinetics and safety of single-dose benapenem (1.0mg) in subjects with mild or moderate Renal Impairment(RI) and healthy subjects. Subjects were enrolled with defined degrees of RI based on eGFR(estimated Glomerular Filtration Rate) calculated by MDRD (Modification of Diet in Renal Disease)formular as follows: nomal renal function(≥90ml/min/1.73m2 ; N=6); mild RI (60-89mL/min/1.73 m2 ; N=6), moderate RI (30-59 mL/min/1.73m2 ; N=6)

Timeline

Start
2019-06-15
Primary completion
2019-10-21
Completion
2019-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Benapenem Small molecule 1 mg Intravenous